相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Oxaliplatin Treatment Alters Systemic Immune Responses
Vanesa Stojanovska et al.
BIOMED RESEARCH INTERNATIONAL (2019)
Anti-tumoral activity of single and combined regorafenib treatments in preclinical models of liver and gastrointestinal cancers
Flavia Fondevila et al.
EXPERIMENTAL AND MOLECULAR MEDICINE (2019)
Research Progress of Diphenyl Urea Derivatives as Anticancer Agents and Synthetic Methodologies
Yi-Cong Wu et al.
MINI-REVIEWS IN ORGANIC CHEMISTRY (2019)
Development of Novel Silyl Cyanocinnamic Acid Derivatives as Metabolic Plasticity Inhibitors for Cancer Treatment
Grady L. Nelson et al.
SCIENTIFIC REPORTS (2019)
Systemic and cardiac susceptibility of immune compromised mice to doxorubicin
Amanda J. Favreau-Lessard et al.
CARDIO-ONCOLOGY (2019)
Indazole Derivatives: Promising Anti-tumor Agents
Yichao Wan et al.
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY (2018)
Recent Advances in the Development of Indazole-based Anticancer Agents
Jinyun Dong et al.
CHEMMEDCHEM (2018)
Autophagic cell death associated to Sorafenib in renal cell carcinoma is mediated through Akt inhibition in an ERK1/2 independent fashion
Leticia Serrano-Oviedo et al.
PLOS ONE (2018)
Recent Advances in Indazole-Containing Derivatives: Synthesis and Biological Perspectives
Shu-Guang Zhang et al.
MOLECULES (2018)
Combining Molecular Scaffolds from FDA Approved Drugs: Application to Drug Discovery
Richard D. Taylor et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
Adoption of Sorafenib for the Treatment of Advanced-Stage Hepatocellular Carcinoma in Oncology Practices in the United States
Helen M. Parsons et al.
LIVER CANCER (2017)
Anti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy?
Rakesh R. Ramjiawan et al.
ANGIOGENESIS (2017)
Diaryl Urea: A Privileged Structure in Anticancer Agents
Laura Garuti et al.
CURRENT MEDICINAL CHEMISTRY (2016)
Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation
Tea Pemovska et al.
NATURE (2015)
Regorafenib Inhibits Colorectal Tumor Growth through PUMA-Mediated Apoptosis
Dongshi Chen et al.
CLINICAL CANCER RESEARCH (2014)
Regorafenib (BAY 73-4506): Antitumor and antimetastatic activities in preclinical models of colorectal cancer
Roberta Schmieder et al.
INTERNATIONAL JOURNAL OF CANCER (2014)
Incorporation of Pazopanib in Maintenance Therapy of Ovarian Cancer
Andreas du Bois et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Rings in Drugs
Richard D. Taylor et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Analysis of the Structural Diversity, Substitution Patterns, and Frequency of Nitrogen Heterocycles among US FDA Approved Pharmaceuticals
Edon Vitaku et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Efficacy and Safety of Axitinib Versus Sorafenib in Metastatic Renal Cell Carcinoma: Subgroup Analysis of Japanese Patients from the Global Randomized Phase 3 AXIS Trial
Takeshi Ueda et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2013)
Sorafenib Inhibits Hypoxia-Inducible Factor-1α Synthesis: Implications for Antiangiogenic Activity in Hepatocellular Carcinoma
Li-ping Liu et al.
CLINICAL CANCER RESEARCH (2012)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity
Scott M. Wilhelm et al.
INTERNATIONAL JOURNAL OF CANCER (2011)
Oxaliplatin but Not Irinotecan Impairs Posthepatectomy Liver Regeneration in a Murine Model
Perry A. Soriano et al.
INTERNATIONAL JOURNAL OF HEPATOLOGY (2011)
The multikinase inhibitor Sorafenib displays significant antiproliferative effects and induces apoptosis via caspase 3, 7 and PARP in B- and T-lymphoblastic cells
Catrin Schult et al.
BMC CANCER (2010)
Pazopanib in Renal Cell Carcinoma
James E. Ward et al.
CLINICAL CANCER RESEARCH (2010)
Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial
Cora N. Sternberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Sorafenib suppresses the cell cycle and induces the apoptosis of hepatocellular carcinoma cell lines in serum-free media
Minoru Tomizawa et al.
EXPERIMENTAL AND THERAPEUTIC MEDICINE (2010)
Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases 1, 2, 3
Dana D. Hu-Lowe et al.
CLINICAL CANCER RESEARCH (2008)
Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: Results from a phase II study
Ezra E. W. Cohen et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling
Scott M. Wilhelm et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity
Rakesh Kumar et al.
MOLECULAR CANCER THERAPEUTICS (2007)
Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: Pharmacokinetic and clinical results
HS Rugo et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
分享论文
